and treatment of dopamine differs considerably. 5 Therefore, identifying biomarkers that could differentiate between PD and MSA would be very useful.
Several lines of evidence demonstrated that inflammatory responses play an essential role in neurodegenerative diseases. 6, 7 It has been shown that neurodegeneration in the pathogenesis of PD and AD is mediated by some inflammatory mediators such as TNFα, IL-1β, and IL-6. 8, 9 Recent studies have also shown that upregulation of these proinflammatory cytokines causes microglial activation, which leads to dopaminergic neurons degeneration and blood-brain barrier (BBB) dysfunction. 10, 11 Klotho (Klt) is a transmembrane molecule that is predominantly expressed in the kidneys and brain. 12 Loss of Klt accelerates human aging, neural degeneration, cognitive impairment, and synapses deficiency in the hippocampus. However, its brain function remains unclear. 13 Accumulating evidence demonstrated that
Klt is functionally related to anti-inflammation 14, 15 and exerts protective effects against age-related diseases such as PD. 13, 16 Another important feature of Klt is that it, together with 1,25-dihydroxy25(OH) D (1,25-(OH)2D), contributes to calcium (Ca)-phosphorus (P) metabolism. [17] [18] [19] Previous reports have shown that 25(OH)D is associated with inflammation and may involve in the pathogenesis of PD. [20] [21] [22] [23] Although both Klt and 25(OH)D are correlated with neuroinflammation 14, 15, 24 and age-related diseases, 13, 16, 22, 23 the association of Klt and 25(OH)D with MSA severity has not been systemically elucidated.
Homocysteine (Hcy) is a key product at the intersection of cysteine and methionine and is associated with neuroinflammation and cognitive dysfunction. 25, 26 Several studies have indicated that some cytokines in the peripheral blood can be regarded as biomarkers to evaluate PD severity. 25, 27 Klt, 25(OH)D and Hcy are not only associated with inflammation and oxidative stress 14, 24, 27 but also play important roles in the pathogenesis of various neurodegenerative diseases. 15, 16, 21, 25, 28, 29 To our knowledge, the independent and combined effects of Klt, 25(OH)D and Hcy have not been investigated in assessing MSA patients yet.
This study was performed to explore whether the cytokines, Klt, to discriminate MSA patients from healthy subjects, as well as distinguishing MSA patients from PD patients.
25(OH)
D
| MATERIALS AND METHODS

| Patients and study design
This cross-sectional study was performed in accordance with the 
| Laboratory measurement
Venous blood samples for Klt, 25(OH)D and Hcy measurements were obtained at 8 am after an overnight fasting. Blood sample (3 mL) was collected from the all the subjects. The serum was separated via centrifugation for laboratory analysis. The serum levels of Klt were detected by R&D Systems ELISA kits (USA). The 25(OH)D levels were determined using competitive chemiluminescence immunoassays (Dia-Sorin, Saluggia, Italy). 32 The serum levels of Hcy were measured by routine laboratory tests, as previously described. • MSA patients, especially in male patients, had significantly higher Hcy serum levels compared with normal subjects.
| Statistical analysis
• Table 3 . The corrected P′ value more than .05 was defined as "no significant differences" among the three groups (controls, MSA, and PD). For additional details, please refer to the Supporting Information. Tables 1 and 2 Table 3 ). In addition, when MSA patients divided into three subtypes (MSA-A, MSA-C, and MSA-P), we also found no statistically significant differences in age among these three groups. 
| RESULTS
| Characteristics of subjects
| Comparisons of Klt/25(OH)D/Hcy between MSA/PD patients and normal subjects
There were significant differences in serum Klt, 25 
| Correlations between Klt, 25(OH)D and HCY Levels and clinical assessing scales
As shown in Table 6 , we performed Spearman's correlation analysis to 
| The ROC analysis of Klt, 25(OH)D and Hcy in the diagnosis of MSA
We performed a ROC curve to examine whether Klt, 25(OH)D, and Hcy could discriminate MSA patients from normal subjects. An area under the curve (AUC) value of .79 (***P<.001, Figure 2A ) was showed in the ROC of Klt analysis; the cutoff was at 2.68 μmol/L (sensitivity: 57%, specificity: 83%). The AUC of Hcy was .66 (***P<.001, Figure 2C) ; the cutoff was 
| The ROC analysis of Klt, 25(OH)D and Hcy in distinguishing male MSA patients from male PD patients
We found serum Klt, 25(OH)D, and Hcy levels in male MSA patients were significantly higher than those in male PD patients (Table 5) , which allowed distinguishing male MSA patients from male PD patients by ROC curves. An area under the curve (AUC) value of .76 (***P<.001, Figure 2E ) was showed in the ROC of Klt analysis; the cutoff was at 2.01 μmol/L (sensitivity: 65%, specificity: 73%). The AUC of Hcy was .64 (**P<.01, Figure 2G) ; the cutoff was at 17. 
| DISCUSSION
Several interesting results were found in our study. The pathogenic mechanisms underlying MSA remain unclear.
Thus, it is important to investigate potential biomarkers which may be implicated in the pathogenesis of MSA and could be used to assess the outcomes and severity of the disease. to an increase of oxidative stress and inflammatory response in the central nervous system, leading to motor neuron degeneration and impairment of cognitive function. 13, 41, 42 Our data indicated serum klt levels significantly differ in patients with PD patients, MSA patients, and healthy controls. The Klt levels exhibited a downward trend in MSA, when compared to the healthy controls. Our study is contrast to the alteration of serum klt levels in multiple sclerosis (MS), 43 shown by decreased levels of Klt in MSA/PD and increased levels in MS.
Significantly lower plasma Klt levels in MSA/PD patients implied that
Klt may attribute to the pathogenesis of the disease. 16, 44 Recently, 25(OH)D has gained much attention due to its crucial role in the pathological mechanism of PD. 21, 22, 28 Other reports have revealed that 25(OH)D deficiency may lead to a high risk of developing MS. 28, 45, 46 Consistent with these reports, we found that in MSA patients exhib- (iv) genetic modifiers, for example, the Klotho genotype and folate or vitamin D medication were not examined in our study; this relatively narrowed the sample size of subjects in our study. Therefore, due to the exploratory nature of our study, comprehensive studies are necessary to conduct in the future.
In conclusion, our study supports the hypothesis that neuroin- 
